Topic Highlight
Copyright ©2013 Baishideng.
World J Radiol. Mar 28, 2013; 5(3): 126-142
Published online Mar 28, 2013. doi: 10.4329/wjr.v5.i3.126
Figure 8
Figure 8 A computed tomography image of a 45-year-old man with clear cell type renal cell carcinoma who had received pre-operative Sorafenib. An exophytic heterogeneously hyperenhanced right renal mass (A) demonstrated homogenous hypoenhancement after the targeted therapy (B). Note an atypical segment 6 hepatic hemangioma and a L1 bone island.